A Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−1439 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs TD 1439 (Primary)
- Indications Cardiovascular disorders; Kidney disorders
- Focus Adverse reactions
- Sponsors Theravance Biopharma
- 27 Feb 2017 Status changed from active, no longer recruiting to completed, as reported in a Theravance Biopharma media release.
- 22 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
- 22 Dec 2016 Status changed from recruiting to active, no longer recruiting.